ArticleProteomics. Clinical applications2022
Plasma biomarkers for systemic inflammation in COVID-19 survivors.
Article in Proteomics. Clinical applications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 4 syntheses or guidelines pooled it, 61 citations in OpenAlex.
- Biomarkers of post-acute infection syndrome: a systematic literature review.Frontiers in immunology · 2026Pooled it
- Persistent inflammatory cytokine signature in long Covid-19 patients: a meta-analysis.Inflammopharmacology · 2026Pooled it
- The Omics Landscape of Long COVID-A Comprehensive Systematic Review to Advance Biomarker, Target and Drug Discovery.Allergy · 2025Pooled it
- Biomarkers in long COVID-19: A systematic review.Frontiers in medicine · 2023Pooled it
- Divergent inflammatory and neurology-related protein levels in long COVID following primary and breakthrough SARS-CoV-2 infections.Communications medicine · 2026Article
- Computational proteomics to enhance personalized treatment of COVID-19 and Long COVID.Clinical proteomics · 2026Review
- A distinct monocyte transcriptional state links systemic immune dysregulation to pulmonary impairment in long COVID.Nature immunology · 2026Article
- Cognition, Cytokines, Blood-Brain Barrier, and Beyond in COVID-19: A Narrative Review.International journal of molecular sciences · 2026Review
- Plasma proteomic profile reveals persistent immune activation in post-acute sequelae of SARS-CoV-2 infection.Frontiers in immunology · 2026Article
- Post-booster longitudinal plasma proteomic changes following BNT162b2 COVID-19 vaccination in Qatar.Frontiers in immunology · 2026Article
- Inflammation from mild COVID-19 results in persistent neurological and behavioral changes in rhesus macaques.Research square · 2025Article
- Long COVID and Biomarker Dysregulation-A Shift Toward Immune Exhaustion?Medicina (Kaunas, Lithuania) · 2025Article
- SIRT2 suppresses aging-associated cGAS activation and protects aged mice from severe COVID-19.Cell reports · 2025Article
- Identification of Putative Serum Autoantibodies Associated with Post-Acute Sequelae of COVID-19 via Comprehensive Protein Array Analysis.International journal of molecular sciences · 2025Article
- Long-term effects of influenza and Bacille Calmette-Guérin vaccination on systemic inflammation.Clinical & translational immunology · 2025Article
- Distinct proteomic signatures in Ethiopians predict acute and long-term sequelae of COVID-19.Frontiers in immunology · 2025Article
- sMR and PTX3 levels associate with COVID-19 outcome and survival but not with Long COVID.iScience · 2024Article
- Article
- A blood-based mRNA signature distinguishes people with Long COVID from recovered individuals.Frontiers in immunology · 2024Article
- Usefulness of the Veterans Health Administration COVID-19 (VACO) Index for Predicting Short-Term Mortality among Patients of the COLOS Study.Journal of clinical medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 1 institution in 1 country.
Funding
Abstract
backgroundWhile the majority of COVID-19 patients fully recover from the infection and become asymptomatic, a significant proportion of COVID-19 survivors experience a broad spectrum of symptoms lasting weeks to months post-infection, a phenomenon termed "post-acute sequelae of COVID-19 (PASC)." The aim of this study is to determine whether inflammatory proteins are dysregulated and can serve as potential biomarkers for systemic inflammation in COVID-19 survivors.
methodsWe determined the levels of inflammatory proteins in plasma from 22 coronavirus disease 2019 (COVID-19) long haulers (COV-LH), 22 COVID-19 asymptomatic survivors (COV-AS), and 22 healthy subjects (HS) using an Olink proteomics assay and assessed the results by a beads-based multiplex immunoassay.
resultsCompared to HS, we found that COVID-19 survivors still exhibited systemic inflammation, as evidenced by significant changes in the levels of multiple inflammatory proteins in plasma from both COV-LH and COV-AS. CXCL10 was the only protein that significantly upregulated in COV-LH compared with COV-AS and HS.
conclusionsOur results indicate that several inflammatory proteins remain aberrantly dysregulated in COVID-19 survivors and CXCL10 might serve as a potential biomarker to typify COV-LH. Further characterization of these signature inflammatory molecules might improve the understanding of the long-term impacts of COVID-19 and provide new targets for the diagnosis and treatment of COVID-19 survivors with PASC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.